MetaCap

Edesa Biotech (EDSA) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed NextCure (NXTC) over the past year, gaining 17.6% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -95.6% for EDSA. NextCure is the larger company by market cap ($29.5 million vs $27.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDSA+17.65%NXTC-38.63%
+1028%+445%-138%
Nov 21, 20251 yearNov 20, 2026
EDSA-95.72%NXTC-90.73%
+12%-46%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDSA versus NXTC key metrics
MetricEDSANXTC
Share price$2.00$6.45
Market cap$27.02M$29.53M
1-day change-8.05%-4.87%
YTD return+40.85%-54.55%
1-year return+17.65%-38.63%
5-year return-95.63%-91.07%
EPS (TTM)$-1.72$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.19M$-55.84M
52-week high$20.32$15.74
52-week low$0.72$1.55
Distance from 52-week high-90.16%-59.02%
Analyst consensusnonenone
Avg. price target upside+716.50%+210.08%
Average volume1.45M79.46K
Shares outstanding13.51M4.58M
Employees1740
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed NXTC by 56.3 percentage points over the past year.

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

EDSA vs NXTC FAQ

Which is bigger, Edesa Biotech or NextCure?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $27.02M for Edesa Biotech (EDSA).

Which stock has performed better over the past year, EDSA or NXTC?

EDSA returned +17.65% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.

Are Edesa Biotech and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons